Palvella Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Net Income	-17.43	18.69	-27.55
Stock-Based Compensation	0.83	0.6	0.43
Other Operating Activities	5.96	-29.85	10.66
Change in Accounts Payable	2.24	-2.25	1.98
Change in Other Net Operating Assets	-2.43	-0.9	-0.36
Operating Cash Flow	-10.84	-13.7	-14.84
Long-Term Debt Issued	18.43	5	-
Net Debt Issued (Repaid)	18.43	5	-
Issuance of Common Stock	60	-	0.03
Other Financing Activities	8.66	-	-
Financing Cash Flow	87.09	5	9.57
Foreign Exchange Rate Adjustments	0	-	-
Net Cash Flow	76.25	-8.7	-5.27
Levered Free Cash Flow	-5.43	-9.96	-
Unlevered Free Cash Flow	-2.74	-9.96	-
Change in Net Working Capital	-5.24	3.15	-

Updated Dec 16, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q